Novartis (NYSE:NVS) Shares Gap Down – What’s Next?

Novartis AG (NYSE:NVS)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $159.99, but opened at $139.94. Novartis shares last traded at $139.4910, with a volume of 1,588,628 shares changing hands.

Novartis News Summary

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Despite the clinical setbacks, Novartis reaffirmed its sales guidance through 2030, indicating that management does not currently expect the failures to undermine near-term commercial performance. Novartis announces trial setback on del-desiran drug
• Neutral Sentiment: A shareholder-investigation notice from SueWallSt alleges potential securities-law violations following the stock’s decline and the trial disclosures. This is an early-stage legal notice rather than a confirmed enforcement action, but it adds headline and litigation risk for investors. Novartis Investigation Notice
• Negative Sentiment: Novartis said del-desiran failed to meet the primary endpoint in the Phase 3 HARBOR study for myotonic dystrophy type 1. The drug did not produce a statistically significant improvement in video hand-opening time, eliminating or delaying a potentially important growth opportunity. Novartis Del-desiran Fails Late-Stage DM1 Study
• Negative Sentiment: The HARBOR failure follows the Phase 3 HORIZON failure for pelacarsen, which lowered harmful Lp(a) cholesterol but did not reduce cardiovascular events. The back-to-back disappointments have raised doubts about Novartis’ pipeline and also pressured other companies developing Lp(a) therapies. Cholesterol drug setback casts doubt over multibillion-dollar race
• Negative Sentiment: Investors are reassessing the value of Novartis’ recent pipeline investments, including candidates obtained through its approximately $12 billion acquisition of Avidity Biosciences. Analysts and investors are now focused on management’s next steps and whether the company can replace the lost growth potential. Novartis Says Neuromuscular Drug Candidate Misses Goal

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft cut shares of Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday. Royal Bank Of Canada initiated coverage on shares of Novartis in a research report on Tuesday. They set a “sector perform” rating on the stock. HSBC raised shares of Novartis from a “reduce” rating to a “hold” rating in a research note on Thursday. Finally, Citigroup restated a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Six research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $141.20.

Novartis Price Performance

The business’s 50-day simple moving average is $155.08 and its two-hundred day simple moving average is $153.29. The stock has a market cap of $262.40 billion, a price-to-earnings ratio of 20.74, a price-to-earnings-growth ratio of 2.67 and a beta of 0.45. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The company had revenue of $14.95 billion during the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. Research analysts expect that Novartis AG will post 8.84 earnings per share for the current year.

Institutional Investors Weigh In On Novartis

A number of institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC lifted its holdings in Novartis by 76.5% in the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock valued at $599,000 after buying an additional 2,666 shares during the period. AQR Capital Management LLC grew its holdings in Novartis by 102.8% during the 1st quarter. AQR Capital Management LLC now owns 22,573 shares of the company’s stock worth $2,516,000 after acquiring an additional 11,444 shares during the period. Empowered Funds LLC bought a new position in shares of Novartis in the 1st quarter worth about $1,764,000. Sivia Capital Partners LLC raised its position in shares of Novartis by 48.0% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock worth $963,000 after acquiring an additional 2,581 shares in the last quarter. Finally, Schnieders Capital Management LLC. acquired a new position in shares of Novartis in the 2nd quarter valued at about $202,000. Institutional investors own 13.12% of the company’s stock.

About Novartis

Novartis AG (NYSE: NVS) is a Switzerland-based pharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company’s portfolio addresses major disease areas including cardiovascular, renal and metabolic conditions, immunology, neuroscience, oncology and hematology.

Novartis markets medicines such as Entresto for certain heart conditions, Cosentyx for inflammatory diseases, Kisqali for breast cancer, Kesimpta for multiple sclerosis, Leqvio for cholesterol management, Pluvicto for certain prostate cancers and Scemblix for chronic myeloid leukemia.